title: Orally administered bovine lactoferrin systemically inhibits VEGF(165)-mediated angiogenesis in the rat.
abstract: Lactoferrin (Lf) systemically suppresses tumor growth and metastasis by unknown mechanisms. We have studied the effect of orally administered iron-unsaturated bovine Lf on angiogenesis induced by VEGF(165) and IL-1-alpha in adult rats using the mesenteric-window angiogenesis assay. VEGF(165) is a major angiogenic factor in most, if not all, tumors and other angiogenesis diseases of clinical relevance. A number of objective angiogenesis variables were analyzed using microscopic morphometry and image analysis. Lf treatment significantly inhibited the VEGF(165)-mediated response in terms of microvessel spatial extension, overall vascularity and incidence of crossover. The response to IL-1-alpha decreased significantly only in terms of microvessel crossover. In vitro, Lf exerted an antiproliferative effect on endothelial cells. To our knowledge, Lf is the first endogenous protein that has been shown to be antiangiogenic following oral administration. The oral administration of Lf thus appears to be of potential interest as an antiangiogenesis treatment modality in the clinical setting. Since tumor growth is angiogenesis dependent, the extensive therapeutic potential warrants further study to elucidate the mechanisms responsible for the angiostatic effect of Lf.
authors.affiliation: Department of Pathology, Institute of Laboratory Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden. klas.norrby@path.gu.se
authors.forename: K
authors.initials: K
authors.lastname: Norrby
authors.forename: I
authors.initials: I
authors.lastname: Mattsby-Baltzer
authors.forename: M
authors.initials: M
authors.lastname: Innocenti
authors.forename: S
authors.initials: S
authors.lastname: Tuneberg
mesh_terms: D000284:Administration, Oral; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D002417:Cattle; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors*; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology; D007781:Lactoferrin / Q000008:administration & dosage / Q000494:pharmacology*; D008222:Lymphokines / Q000037:antagonists & inhibitors*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D015430:Weight Gain / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D016228:Endothelial Growth Factors; D007375:Interleukin-1; D008222:Lymphokines; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D007781:Lactoferrin